Study on the anti-gout activity of chlorogenic acid: improvement on hyperuricemia and gouty inflammation.
Gout is a metabolic disorder associated with hyperuricemia resulting in the deposition of monosodium urate (MSU) crystals in joints and tissues. Lowering serum uric acid (Sur) levels and anti-inflammation are highly essential in treating gout. Chlorogenic acid (CA), as one of the most abundant polyphenols in the Chinese medicines, has been rarely reported to have an anti-gout effect. The model of potassium oxonate (PO)-induced hyperuricemia in mice and MSU crystal-induced inflammation in rats has been established in this study. The potential beneficial effects and mechanisms of CA on hyperuricemia and gouty arthritis were elucidated. The results demonstrated that CA significantly decreased the Sur level by inhibiting the xanthine oxidase (XOD) activity but not increasing the urinary uric acid (Uur) level. In addition, CA also exhibited the effect of suppressing paw swelling. Further investigation indicated that CA improved the symptoms of inflammation induced by MSU crystals by inhibiting the production of proinflammatory cytokines including interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α). The present study suggests that CA may have a considerable potential for development as an anti-gouty arthritis agent for clinical application.
State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, P. R. China , Jiangsu Kanion Pharmaceutical Co. Ltd., Lianyungang 222001, P. R. China.
Zhao-Qing
ZQ
Meng
Zhao-Hui
ZH
Tang
Yun-Xia
YX
Yan
Chang-Run
CR
Guo
Liang
L
Cao
Gang
G
Ding
Wen-Zhe
WZ
Huang
Zhen-Zhong
ZZ
Wang
Kelvin D G
KD
Wang
Wei
W
Xiao
Zhong-Lin
ZL
Yang
D000818:Animals; D002726:Chlorogenic Acid / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D016207:Cytokines / Q000378:metabolism; D004195:Disease Models, Animal; D006073:Gout / Q000139:chemically induced / Q000188:drug therapy* / Q000209:etiology; D006074:Gout Suppressants; D033461:Hyperuricemia / Q000150:complications / Q000188:drug therapy*; D018836:Inflammation Mediators / Q000378:metabolism; D053583:Interleukin-1beta / Q000378:metabolism; D015850:Interleukin-6 / Q000378:metabolism; D008297:Male; D008815:Mice, Inbred Strains; D008517:Phytotherapy; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism; D014527:Uric Acid; D014969:Xanthine Oxidase / Q000097:blood
D016207:Cytokines; D006074:Gout Suppressants; D018836:Inflammation Mediators; D053583:Interleukin-1beta; D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha; D014527:Uric Acid; D002726:Chlorogenic Acid; D014969:Xanthine Oxidase
Chlorogenic acid; Gouty Arthritis; Hyperuricemia; Interleukin-1β; Monosodium Urate Crystals; Xanthine Oxidase